Drugs / TB-403
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02748135 | May 2016 → Oct 2020 | embryonal neoplasm | Oncurious NV | Completed | No outcome recorded |
| Phase 1 | NCT01308684 | May 2011 → Feb 2013 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01308723 | Mar 2011 → Jan 2012 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01148758 | May → Sep 2010 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00702494 | Jun 2008 → Sep 2009 | cancer | BioInvent International AB | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03669393 | Sep 2018 → Nov 2019 | macular telangiectasia type 1, retinal telangiectasia | ThromboGenics | Completed | No outcome recorded |
| Phase 2 | NCT03499223 | Apr 2018 → Jul 2019 | diabetes mellitus, diabetic macular edema | Oxurion | Completed | No outcome recorded |
| Phase 2 | NCT03071068 | Dec 2016 → Apr 2018 | diabetic macular edema | ThromboGenics | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB-403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00702494 ↗ |
| Known as | RG-7334 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109545 ↗ |
| Known as | RO5323441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01308684 ↗ |
| Known as | THR-317 | “3 intravitreal injections of THR-317 4mg approximately 1 month apart” NCT03071068 ↗ |
| Action | Inhibit | “The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1.” NCT00702494 ↗ |
| Modality | Monoclonal antibody | “TB-403 (humanized monoclonal antibody against placental growth factor (PlGF))” NCT02748135 ↗ |
| Route | Intravenous | “multiple intravenous doses of TB-403” NCT00702494 ↗ |
| Target | PGF | “anti-PlGF recombinant monoclonal antibody, 4mg dose” NCT03071068 ↗ |